{
  "trial_id": "NCT01683994",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, Performance status (ECOG), Hemoglobin level, Leukocyte count, ANC (Absolute Neutrophil Count), Platelet count, AST (SGOT) level, ALT (SGPT) level, Total serum bilirubin, Serum albumin, Serum phosphorus, Serum calcium, Serum magnesium, Serum potassium, Lipase level, Creatinine level, Creatinine clearance, Urine protein/urine creatinine ratio (UPCR), PSA levels, Radiographic evidence of disease, Prior treatments (e.g., surgery, radiotherapy, androgen receptor inhibitors), Histopathological confirmation of prostate cancer, Metastatic disease status, Concomitant medications, QT interval (QTcF), HIV status, Peripheral neuropathy grade.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Baseline Prostatic-Specific Antigen (PSA)",
          "PSA levels"
        ],
        [
          "Prior Treatment with Enzalutamide or Abiraterone",
          "Prior treatments (e.g., surgery, radiotherapy, androgen receptor inhibitors)"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Sex: Female",
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "Performance status (ECOG)",
        "Hemoglobin level",
        "Leukocyte count",
        "ANC (Absolute Neutrophil Count)",
        "Platelet count",
        "AST (SGOT) level",
        "ALT (SGPT) level",
        "Total serum bilirubin",
        "Serum albumin",
        "Serum phosphorus",
        "Serum calcium",
        "Serum magnesium",
        "Serum potassium",
        "Lipase level",
        "Creatinine level",
        "Creatinine clearance",
        "Urine protein/urine creatinine ratio (UPCR)",
        "Radiographic evidence of disease",
        "Histopathological confirmation of prostate cancer",
        "Metastatic disease status",
        "Concomitant medications",
        "QT interval (QTcF)",
        "HIV status",
        "Peripheral neuropathy grade"
      ]
    },
    "processed-gen-response": "Age, Performance status (ECOG), Hemoglobin level, Leukocyte count, ANC (Absolute Neutrophil Count), Platelet count, AST (SGOT) level, ALT (SGPT) level, Total serum bilirubin, Serum albumin, Serum phosphorus, Serum calcium, Serum magnesium, Serum potassium, Lipase level, Creatinine level, Creatinine clearance, Urine protein/urine creatinine ratio (UPCR), PSA levels, Radiographic evidence of disease, Prior treatments (e.g., surgery, radiotherapy, androgen receptor inhibitors), Histopathological confirmation of prostate cancer, Metastatic disease status, Concomitant medications, QT interval (QTcF), HIV status, Peripheral neuropathy grade."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Male, Race/Ethnicity, Customized, Region of Enrollment, Performance Status (ECOG), Hemoglobin, Leukocytes, ANC, Platelets, AST (SGOT), ALT (SGPT), Total Serum Bilirubin, Serum Albumin, Serum Phosphorus, Serum Calcium, Serum Magnesium, Serum Potassium, Lipase, Creatinine, Creatinine Clearance, Urine Protein/Urine Creatinine Ratio (UPCR), Prostate-Specific Antigen (PSA) Levels, Bone Metastases, Measurable Disease by RECIST 1.1, Prior Treatment with Androgen Receptor Inhibitors, Prior Treatment with Chemotherapy, Prior Treatment with Radiation Therapy, Prior Treatment with Radionuclide Therapy, Prior Treatment with Small Molecule Kinase Inhibitors, Prior Treatment with Hormonal Therapy, Prior Treatment with Cabozantinib, Prior Treatment with Docetaxel, Prior Treatment with Prednisone, Prior Treatment with Abiraterone, Prior Treatment with Enzalutamide, Prior Treatment with Ketoconazole, Prior Treatment with LHRH or GnRH Agonists, Prior Treatment with Anti-Androgen Agents, Prior Treatment with Cytotoxic Chemotherapy, Prior Treatment with Biologic Agents, Prior Treatment with Investigational Agents, Prior Treatment with Anticoagulants, Prior Treatment with Antiplatelet Agents, Prior Treatment with CYP3A4 Inhibitors/Inducers, Prior Treatment with Antiretroviral Therapy, Prior Treatment with Marrow-Suppressive Therapy, Prior Treatment with Surgery, Prior Treatment with Radiation Therapy, Prior Treatment with Radiosurgery, Prior Treatment with Neurosurgical Resection, Prior Treatment with Brain Biopsy, Prior Treatment with Whole Brain Radiation, Prior Treatment with Epidural Disease, Prior Treatment with Brain Metastases, Prior Treatment with Epidural Disease, Prior Treatment with Brain Metastases, Prior Treatment with Epidural Disease, Prior Treatment with Brain Metastases, Prior Treatment with Epidural Disease, Prior Treatment with Brain Metastases, Prior Treatment with Epidural Disease, Prior Treatment with Brain Metastases, Prior Treatment with Epidural Disease, Prior Treatment with Brain Metastases, Prior Treatment with Epidural Disease, Prior Treatment with Brain Metastases, Prior Treatment with Epidural Disease, Prior Treatment with Brain Metastases, Prior Treatment with Epidural Disease, Prior Treatment with Brain Metastases, Prior Treatment with Epidural Disease, Prior Treatment with Brain",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Male",
          "Sex: Male"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "Baseline Prostatic-Specific Antigen (PSA)",
          "Prostate-Specific Antigen (PSA) Levels"
        ],
        [
          "Prior Treatment with Enzalutamide or Abiraterone",
          "Prior Treatment with Enzalutamide"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Sex: Female",
        "Ethnicity (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "Performance Status (ECOG)",
        "Hemoglobin",
        "Leukocytes",
        "ANC",
        "Platelets",
        "AST (SGOT)",
        "ALT (SGPT)",
        "Total Serum Bilirubin",
        "Serum Albumin",
        "Serum Phosphorus",
        "Serum Calcium",
        "Serum Magnesium",
        "Serum Potassium",
        "Lipase",
        "Creatinine",
        "Creatinine Clearance",
        "Urine Protein/Urine Creatinine Ratio (UPCR)",
        "Bone Metastases",
        "Measurable Disease by RECIST 1.1",
        "Prior Treatment with Androgen Receptor Inhibitors",
        "Prior Treatment with Chemotherapy",
        "Prior Treatment with Radiation Therapy",
        "Prior Treatment with Radionuclide Therapy",
        "Prior Treatment with Small Molecule Kinase Inhibitors",
        "Prior Treatment with Hormonal Therapy",
        "Prior Treatment with Cabozantinib",
        "Prior Treatment with Docetaxel",
        "Prior Treatment with Prednisone",
        "Prior Treatment with Abiraterone",
        "Prior Treatment with Ketoconazole",
        "Prior Treatment with LHRH or GnRH Agonists",
        "Prior Treatment with Anti-Androgen Agents",
        "Prior Treatment with Cytotoxic Chemotherapy",
        "Prior Treatment with Biologic Agents",
        "Prior Treatment with Investigational Agents",
        "Prior Treatment with Anticoagulants",
        "Prior Treatment with Antiplatelet Agents",
        "Prior Treatment with CYP3A4 Inhibitors/Inducers",
        "Prior Treatment with Antiretroviral Therapy",
        "Prior Treatment with Marrow-Suppressive Therapy",
        "Prior Treatment with Surgery",
        "Prior Treatment with Radiosurgery",
        "Prior Treatment with Neurosurgical Resection",
        "Prior Treatment with Brain Biopsy",
        "Prior Treatment with Whole Brain Radiation",
        "Prior Treatment with Epidural Disease",
        "Prior Treatment with Brain Metastases",
        "Prior Treatment with Brain"
      ]
    },
    "processed-gen-response": "Age, Sex: Male, Race/Ethnicity, Region of Enrollment, Performance Status (ECOG), Hemoglobin, Leukocytes, ANC, Platelets, AST (SGOT), ALT (SGPT), Total Serum Bilirubin, Serum Albumin, Serum Phosphorus, Serum Calcium, Serum Magnesium, Serum Potassium, Lipase, Creatinine, Creatinine Clearance, Urine Protein/Urine Creatinine Ratio (UPCR), Prostate-Specific Antigen (PSA) Levels, Bone Metastases, Measurable Disease by RECIST 1.1, Prior Treatment with Androgen Receptor Inhibitors, Prior Treatment with Chemotherapy, Prior Treatment with Radiation Therapy, Prior Treatment with Radionuclide Therapy, Prior Treatment with Small Molecule Kinase Inhibitors, Prior Treatment with Hormonal Therapy, Prior Treatment with Cabozantinib, Prior Treatment with Docetaxel, Prior Treatment with Prednisone, Prior Treatment with Abiraterone, Prior Treatment with Enzalutamide, Prior Treatment with Ketoconazole, Prior Treatment with LHRH or GnRH Agonists, Prior Treatment with Anti-Androgen Agents, Prior Treatment with Cytotoxic Chemotherapy, Prior Treatment with Biologic Agents, Prior Treatment with Investigational Agents, Prior Treatment with Anticoagulants, Prior Treatment with Antiplatelet Agents, Prior Treatment with CYP3A4 Inhibitors/Inducers, Prior Treatment with Antiretroviral Therapy, Prior Treatment with Marrow-Suppressive Therapy, Prior Treatment with Surgery, Prior Treatment with Radiosurgery, Prior Treatment with Neurosurgical Resection, Prior Treatment with Brain Biopsy, Prior Treatment with Whole Brain Radiation, Prior Treatment with Epidural Disease, Prior Treatment with Brain Metastases, Prior Treatment with Brain"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, ECOG Performance Status, PSA at Screening, Gleason Score, Number of Metastatic Sites, Hemoglobin, Leukocytes, ANC, Platelets, AST, ALT, Total Serum Bilirubin, Serum Albumin, Serum Phosphorus, Calcium, Magnesium, Potassium, Lipase, Creatinine, Urine Protein/Urine Creatinine Ratio.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Baseline Prostatic-Specific Antigen (PSA)",
          "PSA at Screening"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Sex: Female",
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Region of Enrollment",
        "Prior Treatment with Enzalutamide or Abiraterone"
      ],
      "remaining_candidate_features": [
        "ECOG Performance Status",
        "Gleason Score",
        "Number of Metastatic Sites",
        "Hemoglobin",
        "Leukocytes",
        "ANC",
        "Platelets",
        "AST",
        "ALT",
        "Total Serum Bilirubin",
        "Serum Albumin",
        "Serum Phosphorus",
        "Calcium",
        "Magnesium",
        "Potassium",
        "Lipase",
        "Creatinine",
        "Urine Protein/Urine Creatinine Ratio."
      ]
    },
    "processed-gen-response": "Age, ECOG Performance Status, PSA at Screening, Gleason Score, Number of Metastatic Sites, Hemoglobin, Leukocytes, ANC, Platelets, AST, ALT, Total Serum Bilirubin, Serum Albumin, Serum Phosphorus, Calcium, Magnesium, Potassium, Lipase, Creatinine, Urine Protein/Urine Creatinine Ratio."
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "age, sex, race, ethnicity, ECOG performance status, hemoglobin, leukocytes, ANC, platelets, AST, ALT, total serum bilirubin, serum albumin, serum phosphorus, calcium, magnesium, potassium, lipase, creatinine, creatinine clearance, urine protein/urine creatinine ratio, PSA levels, number of metastatic lesions, prior treatment with abiraterone or enzalutamide, prior treatment with docetaxel, time since diagnosis of metastatic prostate cancer.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "ethnicity"
        ],
        [
          "Baseline Prostatic-Specific Antigen (PSA)",
          "PSA levels"
        ],
        [
          "Prior Treatment with Enzalutamide or Abiraterone",
          "prior treatment with abiraterone or enzalutamide"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "ECOG performance status",
        "hemoglobin",
        "leukocytes",
        "ANC",
        "platelets",
        "AST",
        "ALT",
        "total serum bilirubin",
        "serum albumin",
        "serum phosphorus",
        "calcium",
        "magnesium",
        "potassium",
        "lipase",
        "creatinine",
        "creatinine clearance",
        "urine protein/urine creatinine ratio",
        "number of metastatic lesions",
        "prior treatment with docetaxel",
        "time since diagnosis of metastatic prostate cancer"
      ]
    },
    "processed-gen-response": "age, sex, race, ethnicity, ECOG performance status, hemoglobin, leukocytes, ANC, platelets, AST, ALT, total serum bilirubin, serum albumin, serum phosphorus, calcium, magnesium, potassium, lipase, creatinine, creatinine clearance, urine protein/urine creatinine ratio, PSA levels, number of metastatic lesions, prior treatment with abiraterone or enzalutamide, prior treatment with docetaxel, time since diagnosis of metastatic prostate cancer."
  }
}